Skip to main content
Erschienen in: Journal of Cancer Education 1/2018

15.07.2016

Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study

verfasst von: Ronald E. Myers, Amy E. Leader, Jean Hoffman Censits, Edouard J. Trabulsi, Scott W. Keith, Anett M. Petrich, Anna M. Quinn, Robert B. Den, Mark D. Hurwitz, Costas D. Lallas, Sarah E. Hegarty, Adam P. Dicker, Charnita M. Zeigler-Johnson, Veda N. Giri, Hasan Ayaz, Leonard G. Gomella

Erschienen in: Journal of Cancer Education | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to explore the effects of a decision support intervention (DSI) and shared decision making (SDM) on knowledge, perceptions about treatment, and treatment choice among men diagnosed with localized low-risk prostate cancer (PCa). At a multidisciplinary clinic visit, 30 consenting men with localized low-risk PCa completed a baseline survey, had a nurse-mediated online DS session to clarify preference for active surveillance (AS) or active treatment (AT), and met with clinicians for SDM. Participants also completed a follow-up survey at 30 days. We assessed change in treatment knowledge, decisional conflict, and perceptions and identified predictors of AS. At follow-up, participants exhibited increased knowledge (p < 0.001), decreased decisional conflict (p < 0.001), and more favorable perceptions of AS (p = 0.001). Furthermore, 25 of the 30 participants (83 %) initiated AS. Increased family and clinician support predicted this choice (p < 0.001). DSI/SDM prepared patients to make an informed decision. Perceived support of the decision facilitated patient choice of AS.
Literatur
1.
Zurück zum Zitat American Cancer Society (2015) Cancer facts & figures 2015. American Cancer Society, Atlanta, GA American Cancer Society (2015) Cancer facts & figures 2015. American Cancer Society, Atlanta, GA
2.
Zurück zum Zitat Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101:1325–3CrossRefPubMedPubMedCentral Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101:1325–3CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–4CrossRefPubMedPubMedCentral Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–4CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Chou R, Croswell JM, Dana T et al (2011) Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762–771CrossRefPubMed Chou R, Croswell JM, Dana T et al (2011) Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762–771CrossRefPubMed
5.
Zurück zum Zitat Cooperberg MR, Carroll PR (2015) Trends in management for patients with localized prostate cancer, 1990–2013. JAMA 314:80–82CrossRefPubMed Cooperberg MR, Carroll PR (2015) Trends in management for patients with localized prostate cancer, 1990–2013. JAMA 314:80–82CrossRefPubMed
6.
Zurück zum Zitat Ritch CR, Grave AJ, Keegan KA et al (2015) Increasing use of observation among men at low risk for prostate cancer mortality. J Urol 193:801–806CrossRefPubMed Ritch CR, Grave AJ, Keegan KA et al (2015) Increasing use of observation among men at low risk for prostate cancer mortality. J Urol 193:801–806CrossRefPubMed
7.
Zurück zum Zitat Weiner AB, Patel SB, Etzioni R et al (2015) National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol 193:95–102CrossRefPubMed Weiner AB, Patel SB, Etzioni R et al (2015) National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol 193:95–102CrossRefPubMed
8.
Zurück zum Zitat Womble PR, Montie JE, Ye Z (2015) Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67:44–50CrossRefPubMed Womble PR, Montie JE, Ye Z (2015) Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67:44–50CrossRefPubMed
9.
Zurück zum Zitat Volk RJ, McFall SL, Cantor SB et al (2014) ‘It’s not like you just had a heart attack’: decision making about active surveillance by men with localized prostate cancer. Psychooncology 23:467–472CrossRefPubMed Volk RJ, McFall SL, Cantor SB et al (2014) ‘It’s not like you just had a heart attack’: decision making about active surveillance by men with localized prostate cancer. Psychooncology 23:467–472CrossRefPubMed
10.
Zurück zum Zitat Xu J, Neale AV, Dailey RK et al (2012) Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med 25:763–770CrossRefPubMedPubMedCentral Xu J, Neale AV, Dailey RK et al (2012) Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med 25:763–770CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Anandadas CN, Clarke NW, Davidson SE et al (2011) Early prostate cancer—which treatment do men prefer and why? BJU Int 107:1762–1768CrossRefPubMed Anandadas CN, Clarke NW, Davidson SE et al (2011) Early prostate cancer—which treatment do men prefer and why? BJU Int 107:1762–1768CrossRefPubMed
12.
Zurück zum Zitat Lin GA, Aaronson DS, Knight SJ et al (2009) Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin 59:379–390CrossRefPubMed Lin GA, Aaronson DS, Knight SJ et al (2009) Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin 59:379–390CrossRefPubMed
13.
Zurück zum Zitat Violette PD, Agoritsas T, Alexander P et al (2015) Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA J Clin 65:239–251CrossRef Violette PD, Agoritsas T, Alexander P et al (2015) Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA J Clin 65:239–251CrossRef
14.
Zurück zum Zitat Stacey D, Légaré F, Col NF et al (2014) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 1, CD001431 Stacey D, Légaré F, Col NF et al (2014) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 1, CD001431
15.
Zurück zum Zitat Gomella LG, Lin J, Hoffman-Censits J et al (2010) Enhancing prostate cancer care through the multidisciplinary approach: a 15-year experience. J Oncol Pract 6:e5–e10CrossRefPubMedPubMedCentral Gomella LG, Lin J, Hoffman-Censits J et al (2010) Enhancing prostate cancer care through the multidisciplinary approach: a 15-year experience. J Oncol Pract 6:e5–e10CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Vernon SW, Myers RE, Tilley BC (1997) Development and validation of an instrument to measure factors related to colorectal cancer screening adherence. Cancer Epidemiol Biomarkers Prev 6:825–832PubMed Vernon SW, Myers RE, Tilley BC (1997) Development and validation of an instrument to measure factors related to colorectal cancer screening adherence. Cancer Epidemiol Biomarkers Prev 6:825–832PubMed
17.
Zurück zum Zitat Tiro JA, Vernon SW, Hyslop T et al (2005) Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 14:2855–2861CrossRefPubMed Tiro JA, Vernon SW, Hyslop T et al (2005) Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 14:2855–2861CrossRefPubMed
18.
19.
Zurück zum Zitat Wilt TJ (2014) Management of low risk and low PSA prostate cancer: long term results from the Prostate Cancer Intervention versus Observation Trial. Recent Results Cancer Res 202:149–169CrossRefPubMed Wilt TJ (2014) Management of low risk and low PSA prostate cancer: long term results from the Prostate Cancer Intervention versus Observation Trial. Recent Results Cancer Res 202:149–169CrossRefPubMed
20.
Zurück zum Zitat Heidenreich BPJ, Bellmunt J et al (2013) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update, 2013. Euro Urol 65:124–137CrossRef Heidenreich BPJ, Bellmunt J et al (2013) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update, 2013. Euro Urol 65:124–137CrossRef
21.
Zurück zum Zitat Hayes JH, Ollendorf DA, Pearson SD et al (2010) Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 304:2373–2380CrossRefPubMedPubMedCentral Hayes JH, Ollendorf DA, Pearson SD et al (2010) Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 304:2373–2380CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Christie DR, Sharpley CF, Bitsika V (2015) Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer. Psych-Oncol 24:1002–1011CrossRef Christie DR, Sharpley CF, Bitsika V (2015) Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer. Psych-Oncol 24:1002–1011CrossRef
23.
Zurück zum Zitat Jang TL, Bekelman JE, Liu Y et al (2010) Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 170:440–450CrossRefPubMedPubMedCentral Jang TL, Bekelman JE, Liu Y et al (2010) Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 170:440–450CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Shappley WV, Kenfield SA, Kasperzyk JL et al (2009) Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 27:4980–4985CrossRefPubMedPubMedCentral Shappley WV, Kenfield SA, Kasperzyk JL et al (2009) Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 27:4980–4985CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat National Comprehensive Cancer Network guidelines for prostate cancer (2015) Corrections to Version 1.2015 of the NCCN Guidelines for Prostate Cancer. National Comprehensive Cancer Network guidelines for prostate cancer (2015) Corrections to Version 1.2015 of the NCCN Guidelines for Prostate Cancer.
26.
Zurück zum Zitat Chen RC, Rumble B, Loblaw DA et al. (2016) Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol doi: 10.1200/JCO.2015.65.7759. Chen RC, Rumble B, Loblaw DA et al. (2016) Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol doi: 10.​1200/​JCO.​2015.​65.​7759.
Metadaten
Titel
Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
verfasst von
Ronald E. Myers
Amy E. Leader
Jean Hoffman Censits
Edouard J. Trabulsi
Scott W. Keith
Anett M. Petrich
Anna M. Quinn
Robert B. Den
Mark D. Hurwitz
Costas D. Lallas
Sarah E. Hegarty
Adam P. Dicker
Charnita M. Zeigler-Johnson
Veda N. Giri
Hasan Ayaz
Leonard G. Gomella
Publikationsdatum
15.07.2016
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 1/2018
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-016-1073-7

Weitere Artikel der Ausgabe 1/2018

Journal of Cancer Education 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.